We used RNA interference, which causes sequence-specific degradation of target mRNAs to suppress the production of parathyroid hormone by cells of patients with secondary hyperparathyroidism in vitro and in vivo. Transfection of small interfering RNA (siRNA) against human parathyroid hormone into monolayers of parathyroid cells cultured from these patients caused a dose-dependent decrease of secretion and mRNA levels with 80% or more suppression using 40 nM siRNA. Parathyroid cells cultured on nonadherent plastic produced spheroid cell aggregates which secreted parathyroid hormone for more than 150 days. Transfection of these spheroids with 50 nM targeted siRNA decreased parathyroid hormone production to 20% of the control level, with half of them being suppressed for 50 days. When parathyroid cells were transplanted into the livers of athymic nude mice, plasma human parathyroid hormone rose to 100-300 pg/ml within one month and remained at about this level for at least 39 days. Systemic delivery of hormone-targeted siRNA into these mice caused a dosedependent suppression of circulating human parathyroid hormone for at least one month, with a maximum 80% suppression achieved by 80 lg of siRNA. Our study shows that hormone secretion by parathyroid cells of patients with secondary hyperparathyriodism can be suppressed both in vitro and in vivo by targeted siRNAs. Secondary hyperparathyroidism (2HPT) is one of the most important complications of chronic kidney disease (CKD). In CKD, parathyroid hormone (PTH) secretion is stimulated by hypocalcemia, phosphate retention, and reduced levels of activated vitamin D3 (1,25-D).
We used RNA interference, which causes sequence-specific degradation of target mRNAs to suppress the production of parathyroid hormone by cells of patients with secondary hyperparathyroidism in vitro and in vivo. Transfection of small interfering RNA (siRNA) against human parathyroid hormone into monolayers of parathyroid cells cultured from these patients caused a dose-dependent decrease of secretion and mRNA levels with 80% or more suppression using 40 nM siRNA. Parathyroid cells cultured on nonadherent plastic produced spheroid cell aggregates which secreted parathyroid hormone for more than 150 days. Transfection of these spheroids with 50 nM targeted siRNA decreased parathyroid hormone production to 20% of the control level, with half of them being suppressed for 50 days. When parathyroid cells were transplanted into the livers of athymic nude mice, plasma human parathyroid hormone rose to 100-300 pg/ml within one month and remained at about this level for at least 39 days. Systemic delivery of hormone-targeted siRNA into these mice caused a dosedependent suppression of circulating human parathyroid hormone for at least one month, with a maximum 80% suppression achieved by 80 lg of siRNA. Our study shows that hormone secretion by parathyroid cells of patients with secondary hyperparathyriodism can be suppressed both in vitro and in vivo by targeted siRNAs. Secondary hyperparathyroidism (2HPT) is one of the most important complications of chronic kidney disease (CKD). In CKD, parathyroid hormone (PTH) secretion is stimulated by hypocalcemia, phosphate retention, and reduced levels of activated vitamin D3 (1,25-D) . 1 When 2HPT is left untreated, parathyroid (PT) hyperplasia ensues and precipitates hypercalcemia and hyperphosphatemia, leading to ectopic calcification and vascular sclerosis, which determine the prognosis of dialysis patients. [2] [3] [4] Although 1,25-D pulse therapy is effective for 2HPT, hyperplastic PT cells gradually develop resistance to 1,25-D. Once PT cells acquire resistance to 1,25-D, the only treatment of choice is parathyroidectomy or necrotic destruction of the PT glands by percutaneous ethanol injection. However, when surgical interventions are selected, postoperative PTH control is difficult, and PT autograft is associated with the risk of 2HPT relapse.
Vitamin D3 resistance in 2HPT involves multiple mechanisms that compromise the regulation of PTH production by vitamin D3 and calcium. Vitamin D3 receptor (VDR) levels are decreased in the PT glands of dialysis patients and animal models of renal failure. [5] [6] [7] [8] [9] The binding of normal rat VDRs to vitamin D responsive elements can be inhibited by uremic toxins, 10 and VDRs from renal failure rats have reduced ability to bind vitamin D responsive elements. 10, 11 Moreover, retinoid X receptor levels are decreased in rats with renal failure, 11 further impairing VDR activity, because VDR exerts its action in the form of heterodimer with retinoid X receptor. 12 As 1,25-D is responsible for upregulation of VDR, a vicious cycle begins in 2HPT and perpetuates insufficient 1,25-D actions. Furthermore, calcium sensing receptors (CaR) levels are decreased in hyperplastic PT glands of patients with uremic hyperparathyroidism, 13 which, in part, accounts for the elevated setpoint of calcium concentration for inhibiting PTH secretion in 2HPT 14 and may affect the action of type II calcimimetics that suppress PTH secretion via the allosteric modulation of CaR. 15 RNA interference (RNAi) is a mechanism of cell that inhibits gene expression by causing the degradation of specific mRNAs or hindering the transcription of specific genes. 16 Double-stranded small interfering RNAs (siRNAs) play a key role in activating the RNAi machinery that specifically degrades mRNAs with sequences complementary to siRNA. 16 Discoveries that the RNAi machinery can be activated by siRNAs in cultured mammalian cells 17 and mice 18 provided impetus to exploring RNAi for therapeutic purposes. Because of the mechanism of action, RNAi would provide a specific therapeutic means that can circumvent vitamin D3 resistance and control PTH production in 2HPT complicating CKD.
In this study, we examined both in vitro and in vivo the potential use of RNAi to suppress PTH production in PT cells of 2HPT patients. First, we used monolayer cultures of PT cells from 2HPT patients to evaluate short-term effects of siRNAs targeted to human PTH mRNA. Then, we established a spheroid culture of PT cells to examine long-term effects of siRNAs. Finally, we transplanted PT cells into the liver of athymic nude mice and evaluated in vivo effects of siRNAs.
RESULTS

Effects of siRNAs in monolayer cultures of PT cells
PT cells were dissociated from PT glands of 2HPT patients and, after removal of fibroblasts, incubated on collagen type I-coated plates. Immunostaining showed that 90% or more cells were positive for PTH ( Figure 1) . Within a few weeks of culture, PTH-positive cells were found in polygonal clusters surrounded by overgrowing fibroblasts (Figure 1 ).
PTH secretion in monolayer PT cells reached a peak after approximately 1 week of culture, decreased afterwards, and became marginal by 3 weeks of culture (Figure 2a ). The observed single-peak changes in PTH secretion were shared by all specimens, whereas the amount of secreted PTH varied from one specimen to another. Transfection of anti-PTH siRNA caused dose-dependent suppression of PTH secretion (Figure 2a ). More than 75% of the peak PTH secretion was suppressed at a final concentration of 40 nM (86.0±3.6% suppression; N ¼ 6). Negative control siRNA had no appreciable effects at the same concentration. PTH mRNA levels were determined by real-time PCR after transfection of 50 nM siRNA (Figure 2b ). Following transfection of negative control siRNA, PTH mRNA levels reached a peak on day 1 and declined. In contrast, PTH mRNA levels in the anti-PTH siRNA-transfected cultures decreased significantly on day 1 after transfection (86.9±1.9% suppression; Po0.05 vs control siRNA; N ¼ 3) and remained significantly lower than those in the control cultures. Three siRNAs targeting different parts of PTH mRNA showed similar suppressing effects (data not shown), excluding the possibility of offtarget effects.
Long-term spheroid culture of functional PT cells
To evaluate long-term effects of siRNAs, we attempted threedimensional culture. When PT cells were cultured on roundbottom nonadherent 96-well plates, the cells coalesced to each other and, within a few days, formed an aggregate, or 'spheroid.' Spheroid formation was highly reproducible when PT cells were plated at 5 Â 10 4 to 1 Â 10 6 cells/well. Spheroids were also formed at 1 Â 10 4 cells/well or less; however, spheroids shrank and PTH secretion ceased rapidly. Spheroid formation was inconsistent at 1 Â 10 7 cells/well or higher (data not shown).
The spheroids had a diameter of 100-500 mm and were not a simple cell cluster ( Figure 3 ). Each spheroid consisted of compact cell masses separated by acellular spaces. Some spheroids were covered by a layer of cells. Immunostaining revealed that PTH production occurred in the cell masses, but not in the surface cell layer ( Figure 3 ). No proliferation of fibroblasts was observed on the surface of nonadherent plates.
In PT cell spheroids, PTH secretion peaked within 2-3 weeks of culture, followed by a period of steady secretion that continued for about 2 months, and began to decline (Figure 4a ). This pattern of PTH secretion was consistent among different specimens, whereas the amount of secreted PTH varied with the specimen and the number of cells inoculated per well. The size of spheroid did not change during the steady secretion period; however, it began to decrease as PTH secretion dwindled. Cells positive for Ki-67, a marker for cell proliferation, were hardly seen in the spheroids throughout the culture period ( Figure 4b ). Likewise, cells expressing active caspase-3, a marker for apoptosis, were very few during the steady period; however, they increased later as the spheroid size and PTH secretion decreased ( Figure 4b ).
To determine the functionality of PT cells in spheroid culture, we examined the expression of CaR and the responsiveness to changes in extracellular calcium concentration ( Figure 5 ). Immunostaining demonstrated that PT cells in spheroids continued to express CaR on cell membranes throughout the culture period ( Figure 5a ). When PT cell spheroids were incubated in a low-calcium medium (0.5 mM), PTH secretion was increased, whereas the secretion was decreased on incubation in a high-calcium medium (3.0 mM), as compared with that seen in the standard medium containing 1.25 mM calcium (Figure 5b ).
Effects of siRNAs in PT cell spheroids
To determine the effect of siRNAs in PT cell spheroids, monolayer PT cells were transfected with siRNAs and replated onto nonadherent plates. Similar to nontransfected PT cells, the cells transfected with negative control siRNA formed spheroids within a few days of replating and secreted PTH in a pattern characterized by a peak occurring within 2-3 weeks after replating and a subsequent steady secretion period (Figure 6a ). The anti-PTH siRNA-transfected cells also formed spheroids within a few days after replating. However, the peak of secretion was largely suppressed (85.9±5.7% suppression; N ¼ 8) and the period of steady secretion was replaced by a gradual increase, with PTH secretion reaching the control levels by the end of 2-3 months of culture (Figure 6a ).
Immunostaining revealed that the amount of PTHsecreting cells changed in parallel with the PTH secretion level (Figure 6b ). In PT cell spheroids transfected with negative control siRNA, PTH immunoreactivity was intense and widely distributed at the peak of secretion (day 16 in Figure 6b ), became less intense during the steady secretion (day 42) and increased its intensity whereas becoming less extensive during the steady secretion period (day 82). Changes in PTH immunoreactivity also overlapped those in PTH secretion in anti-PTH siRNA-transfected cells. Early after spheroid formation, PTH immunoreactivity was scattered (day 16 in Figure 6b) ; it became very weak when the secretion was suppressed (day 42), and became intense and widely distributed when PTH secretion increased toward the control levels (day 82).
Frequencies of cell proliferation and apoptosis were similar between the negative control siRNA and anti-PTH siRNA-transfected spheroids ( Figure 7) . Thus, the observed suppression of PTH secretion reflected the specific effect of siRNA on PTH secretion.
Effects of siRNAs on human PT cells transplanted into athymic nude mice
To evaluate the effects of siRNAs in an in vivo setting, 2.7 Â 10 6 PT cells were transplanted into the liver of athymic nude mice. After 1 month, the plasma concentrations of intact human PTH were 100-300 pg/ml and remained at these levels throughout the 39 days of experimental period ( Figure 8) . The PTH secretion level differed from specimen to specimen. In the absence of transplantation, PTH concentrations remained below the lower limit of the assay range (15 pg/ml). siRNAs were introduced into the mice via the tail vein by hydrodynamic method. Negative control siRNA had no appreciable effect on the plasma human PTH concentrations until the end of experimental period (a maximum of 13.7±6.5% suppression on day 2 after transfection; N ¼ 4; Figure 8 ). In contrast, anti-PTH siRNA caused dosedependent suppression of human PTH secretion. On day 8 after siRNA introduction, plasma PTH levels were decreased by 56.8 ± 6.8% (N ¼ 4), 70.1 ± 10.7% (N ¼ 3) , and 78.5±0.6% (N ¼ 3) of the pre-introduction levels with 40, 80, and 120 mg of siRNA, respectively. The onset of suppression was similar with different doses of siRNA, occurring on day 2 after siRNA introduction. The duration of suppression varied with the dose of siRNA, with 60% or greater suppression continuing for more than 2 weeks with 120 mg of siRNA.
DISCUSSION
In this study, we explored in vitro and in vivo the use of RNAi to suppress PTH production by PT cells from advanced 2HPT patients. First, we examined the in vitro effects of siRNAs using monolayer PT cell cultures. Results showed that anti-PTH siRNAs induced dose-dependent suppression of PTH secretion and PTH mRNA levels, demonstrating that anti-PTH siRNAs triggered the RNAi machinery in PT cells of advanced 2HPT patients, leading to the degradation of PTH mRNA and the suppression of PTH production.
PTH production in monolayer PT cells dwindled after 15-20 days of culture, coinciding with robust fibroblast proliferation. Primary cultures of dialysis patients' PT cells have been used as an in vitro model of 2HPT, and response of PTH production to calcium, phosphate or 1,25-D has been investigated. 19, 20 Methods have been reported for long-term culture of human PT cells; [19] [20] [21] however, our attempts with these methods were unsuccessful primarily because of overwhelming fibroblast proliferation. Neither D-valine-substituted medium 22 nor removal of fibroblasts with antifibroblast antibody-conjugated magnetic beads was sufficiently effective.
For long-term culture of functioning PT cells, we resorted to three-dimensional culture or 'spheroid culture.' When PT cells from 2HPT patients were plated on nonadherent plates, they formed 'spheroids' and continued to secrete PTH for 3 months or more. No fibroblast proliferation was observed on the surface of nonadherent plates. The PT cell spheroids consisted of compact cell masses separated by acellular, substrate-filled spaces, an architecture similar to that of 'organoids' or 'pseudoglands' formed by bovine PT cells cultured in roller bottles 23 or in collagen matrix. 24 PTH production occurred in compact cell masses, but not in a layer of cells observed on the surface of some spheroids. These findings suggest that whereas nonadherent plates inhibited proliferation of anchorage-dependent fibroblasts, remaining fibroblasts were sorted out of PT cell aggregates, formed a layer on the surface of spheroid and ceased proliferation due to contact inhibition. The relationship between fibroblasts and PT cells in spheroid is reminiscent of that observed between the capsule and glandular cells in PT hyperplasia. 23, 24 In general, PT cells rapidly lose functionality in monolayer cultures 25, 26 although two studies reported that PT cells from 2HPT patients retained functionality for up to 5 months 19 or 60 days. 20 Besides the fibroblast overgrowth, the short-lived functionality of monolayer PT cells has been ascribed to their proliferation-associated dedifferentiation and insufficient cell-to-cell contact. Earlier studies associated avid proliferation of PT cells with decreased functionality. [27] [28] [29] In fact, inhibition of proliferation was found to help monolayer PT cells retain differentiated function. 24, 30 A study reported that PTH secretion was more active when PT cells were plated at a high density to allow cell-to-cell contact and, possibly, contact inhibition. 31 In this regard, multicellular aggregates of PT cells obtained by roller bottle culture 23 or in collagen matrix 24 were both characterized by negligible proliferation and high levels of cell-to-cell contact, indicating the importance of three-dimensional tissue-like architecture. Our spheroid culture of PT cells was benefited from these features: PT cells were organized in three-dimensional configuration, provided with sufficient cell-to-cell contact, and exhibited virtually no proliferative activity. Thus, PT cells in spheroids continued to express CaR and retained the responsiveness to extracellular calcium concentration for 2-3 months of experimental period.
The PT cell spheroids had a peak PTH secretion after 2-3 weeks of culture and entered a period of steady secretion that lasted for at least 3 months. No substantial cell proliferation was observed throughout the culture period. Apoptosis was few until the later stage of steady secretion when the spheroids began to shrink and showed decreased PTH secretion. These findings suggest that the observed changes in PTH secretion mirrored those in the secretion capacity of individual PT cells until the later stage of steady secretion. In 2HPT, PT cells are exposed to stimuli for PTH secretion, including decreased 1,25-D and calcium and increased phosphate. 1 Two studies claimed success in long-term monolayer cultures of functional human PT cells and attributed the success, in part, to the choice of medium: a low-calcium (0.09 mM) medium 20 and a phosphate-rich (5.6 mM) medium. 19 We used a medium containing moderate concentrations of calcium (1.25 mM) and phosphate (2.6 mM), which would be less stimulating to PT cells than the above two media or the in vivo environment of 2HPT patients. Thus, it is possible that the observed peak and steady state of PTH secretion represented, respectively, a stimulated state and a baseline-like state of PT cells, with the stimulated state persisting until the cells adjusted to a new environment. In our monolayer cultures, the stimulated state was truncated and the baseline-like state was barely recognizable probably because of insufficient cell-to-cell contact and fibroblast overgrowth. In spheroid cultures, anti-PTH siRNA suppressed PTH production by 90% or more for approximately 1 month, and 50% or greater suppression persisted for at least 50 days. We chose to transfect monolayer PT cells, then, transfer them to nonadherent plates, because transfecting PT cell spheroids resulted in poor suppression of PTH secretion or cell damage at higher concentrations of siRNA. The observed long-term effect of anti-PTH siRNA is partly attributable to the chemical modifications of siRNAs. It can also be related to the characteristics of PT cells. PT cells in spheroids exhibited virtually no proliferative activity, which may have minimized cell division-associated dilution of transfected siRNA.
Furthermore, PT cells of 2HPT patients are characterized by decreased nuclease activities that cause PTH mRNA accumulation and PTH overproduction 32 and would prolong half-lives of siRNAs. These characteristics of PT cells of 2HPT patients are advantageous to clinical application of siRNAs.
Results showed that anti-PTH siRNAs were effective for gene knockdown of PTH in PT cells in vitro. However, properties of cells can change when transferred to an in vitro culture environment. Therefore, we transplanted human PT cells into the liver of nude mice immediately after their isolation to preserve their in vivo state. We chose the liver for transplantation because systemically introduced nucleic acids are delivered most efficiently to hepatocytes with the hydrodynamic method. 33 After 1 month of transplantation, intact human PTH was found in high concentrations in the blood of the recipient mice and retained these levels for at least 1 month, indicating that the transplanted human PT cells maintained their secretion function for at least 2 months. These are in line with Roussanne et al. 19 who subcutaneously transplanted PT cells of 2HPT patients into nude mice and found that intact human PTH concentrations reached 41000 pg/ml and retained a mean level of 390 pg/ml 9 months after transplantation. Hydrodynamic delivery of anti-PTH siRNA caused dose-dependent suppression of PTH secretion. A maximum of 80% suppression was achieved by 80 mg of siRNA, and some 60% suppression continued for up to 1 month with 120 mg. These findings provided evidence that the systemically delivered siRNA survived in the circulation, reached the cytoplasm of the transplanted human PT cells and efficiently suppressed PTH secretion. Thus, anti-PTH siRNAs were effective in suppressing PTH production in vivo, and the effect persisted for 6 weeks or longer.
This study demonstrated the applicability of siRNAmediated RNAi activation to the therapy of 2HPT. We are currently developing a method in which gels containing siRNA and transfection reagents are injected into the inside and surroundings of PT glands in a manner similar to percutaneous ethanol injection therapy. Use of recently developed chemical modifications of siRNAs, such as addition of cholesterols to siRNAs to improve cell membrane penetration, 34 will help enhance the efficiency of transfection and prolong the half-lives of siRNAs. RNAi-based approach would reduce the need for calcimimetics and/or vitamin D3 supplementation and allow easier postoperative PTH control.
MATERIALS AND METHODS
This study protocol was approved by the Institutional Review Board of Tokai University School of Medicine. Human materials were used under the informed consent of the patients.
Preparation and monolayer culture of human PT cells The PT glands were removed from 17 CKD patients who were diagnosed with advanced 2HPT and indicated for surgical interventions. The glands from different patients were handled separately, and PT cells from different patients were not mixed. The glands were minced, washed with DMEM/Ham's F12 medium (Wako, Osaka, Japan) supplemented with 5% fetal calf serum and digested at 37 1C for 30 min with 0.2% collagenase type II (Worthington, Lakewood, NJ, USA). PT cells were dispersed by pipetting and filtered through a 70 mm mesh. After repeated washing, red blood cells were removed by a lysing solution (VersaLyse; Beckman Coulter, Fullerton, CA, USA). PT cells were washed and resuspended in DMEM/ F12 þ GlutaMax-1 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum, 50 U/ml penicillin and 50 mg/ml streptomycin and incubated on tissue culture-treated plates in a humidified atmosphere of 95% air/5% CO 2 at 37 1C. On the following day, adherent cells were harvested by trypsinization and resuspended at a density of 1 Â 10 7 cells/80 ml in phosphate-buffered saline without calcium and magnesium (PBS) containing 0.5% bovine serum albumin, mixed with 20 ml of anti-fibroblast antibodyconjugated magnetic microbeads suspension (Anti-Fibroblast MicroBeads; Miltenyi Biotec, Bergisch Gladbach, Germany) and incubated at room temperature for 30 min. Cells were washed and loaded onto a magnetic column of auto-MACS cell sorting system (Miltenyi Biotec). Fibroblast-depleted cells were collected, resuspended in DMEM/F12 þ GlutaMax-1 medium supplemented as above, inoculated at a density of 5 Â 10 5 cells/well onto collagen type I-coated 24-well plates (Becton Dickinson Labware, Franklin, NJ, USA) and incubated in a humidified atmosphere of 95% air/5% CO 2 at 37 1C. Medium was renewed every other day.
In vitro siRNA transfection siRNAs targeted to human PTH mRNA (anti-PTH siRNAs; PTH-HSS108784, PTH-HSS108785, and PTH-HSS108786 of Stealth RNAi) and negative control siRNA (Low GC) were purchased from Invitrogen (Carlsbad, CA, USA). Fibroblast-depleted PT cells were incubated for a few hours at 5 Â 10 5 cells/well on collagen type I-coated 24-well plates until 70-90% confluency was achieved. Then, siRNA mixed with a transfection reagent (RNAiMax; Invitrogen) at a ratio of 6 pmol to 1 ml was added to the cultures. Medium was changed after overnight incubation in a humidified atmosphere of 95% air/5% CO 2 at 37 1C.
Quantitative real-time PCR Total RNA was extracted using RNAqueous-4PCR kit (Applied Biosystems, Foster City, CA, USA) and converted to cDNA using SuperScript III First-Strand Synthesis System (Invitrogen). Resulting cDNA solution was diluted 60-, 120-, 240-, and 480-fold with distilled water and used as templates. Reaction mixture was prepared as described in the instruction manual of a kit (TaqMan Gene Expression Assays; Applied Biosystems) containing primers and probes for intact human PTH (Assay ID: Hs00174888_m1) and eukaryotic 18S rRNA used as an internal control. PCR was performed on an ABI PRISM 7700 Sequence Detector (Applied Biosystems). Data were analyzed by the comparative C t method, and the amount of PTH mRNA was expressed relative to that of 18S rRNA.
Spheroid culture of human PT cells Fibroblast-depleted PT cells were suspended in DMEM/ F12 þ GlutaMax-1 medium supplemented as above and plated at 1 Â 10 4 to 1 Â 10 6 cells/well onto nonadherent round-bottom 96-well plates (SUMILON Celltight Spheroid 96U; Sumitomo Bakelite, Tokyo, Japan). The cells were incubated in a humidified atmosphere of 95% air/5% CO 2 at 37 1C. Medium was renewed every other day. To examine the effect of siRNAs in spheroids, monolayer PT cells were transfected with siRNA as described above and replated on nonadherent round-bottom 96-well plates for spheroid formation. In some experiments, PT cell spheroids were incubated in a medium containing either 0.5 mM or 3.0 mM calcium, as opposed to 1.25 mM calcium in the standard medium. These media were prepared by adding CaCl 2 to calcium-free DMEM/F12 þ GlutaMax-1 medium (Gibco Invitrogen). Concentration of ionized calcium was determined using a calcium-selective electrode after the medium was completed with fetal calf serum and antibiotics as described above.
Immunohistochemistry PT cell spheroids were fixed with 4% paraformaldehyde and frozen in OCT compound (Sakura Finetechnical, Tokyo, Japan). Tenmicrometer thick Sections of 10 mm were dried and rinsed with PBS and blocked with 1% blocking reagent (Invitrogen). Primary antibodies included anti-PTH antibody (sc-9678; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Ki-67 antibody (sc-23900; Santa Cruz Biotechnology), anti-active caspase-3 antibody (Promega, Madison, WI, USA) and anti-calcium-sensing receptor antibody (sc-32181; Santa Cruz Biotechnology). Bound antibodies were visualized using Tyramid Signal Amplification Kit (Invitrogen) and observed under the fluorescent microscope.
Human PT cell transplantation in athymic nude mice PT cells were suspended in PBS, and 50 ml of cell suspension containing 2.7 Â 10 6 cells was injected into the liver of 4-to 5-weekold athymic nude mice (Nihon CLEA, Tokyo, Japan) under anesthesia. After 1 month, blood was sampled from the tail vein for quantification of intact human PTH, and siRNA was introduced into the recipient mice. siRNA was resolved in 3.1 ml of a hydrodynamic injection solution (TransIT-QR Hydrodynamic Delivery Solution; Mirus, Madison, WI, USA) and injected into the tail vein within 4-7 s. The plasma concentration of intact human PTH was measured at the time points described in the figure legends.
PTH determination
Intact human PTH was quantified by ELISA (hPTH-EASIA; BioSource Europe SA, Nivelles, Belgium). For cultured PT cells, medium was renewed 24 h before sampling. Samples were centrifuged, and supernatants were diluted with a fresh medium to adjust the PTH concentration within the assay range (15-1, 200 pg/ml). All samples and standards were duplicated, and average values were used for analysis.
Statistical analysis
Data are shown as mean ± s.d. Differences were analyzed by twotailed Student's t-tests. A P-value of o0.05 was considered statistically significant.
